| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
17,087 |
16,536 |
$2.00M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
25,215 |
24,845 |
$1.69M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
9,560 |
9,469 |
$649K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
8,391 |
8,277 |
$416K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
4,576 |
4,466 |
$312K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
9,068 |
8,821 |
$240K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
2,518 |
2,457 |
$234K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,152 |
1,136 |
$118K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
4,394 |
4,287 |
$98K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
4,323 |
4,200 |
$63K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
634 |
623 |
$31K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,181 |
1,141 |
$27K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,958 |
1,930 |
$22K |
| 99215 |
Prolong outpt/office vis |
147 |
147 |
$14K |
| 87081 |
|
1,292 |
1,281 |
$8K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
528 |
519 |
$6K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
113 |
111 |
$6K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
110 |
110 |
$4K |
| 81002 |
|
1,140 |
1,123 |
$2K |
| 81025 |
|
281 |
278 |
$2K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
60 |
60 |
$1K |
| 90686 |
|
34 |
34 |
$531.00 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
36 |
36 |
$261.59 |
| 82948 |
|
16 |
14 |
$40.05 |